The debriefing session of "Japan Agency for Medical Research and Development" = AMED, which supports the development of vaccines for the new coronavirus in Japan, was held on the 4th, and domestic researchers and companies reported on the development status.
In connection with the development of domestic vaccines for the new coronavirus, the government provided support to 16 research themes through AMED last year.
Seven groups reported on the development status at the AMED results report meeting held online on the 4th.
Of these, Professor Ryuichi Morishita of Osaka University Graduate School, who is conducting joint research with a company on a new type of vaccine using DNA that is in the final stage of clinical trials, published a summary of the initial stage of trial results and made immunity. Reported that work and safety were confirmed.
In addition, in the development of the same type of "mRNA vaccine" as Pfizer's vaccine, groups such as the pharmaceutical giant "Daiichi Sankyo", which has begun clinical trials in the early stages, used only a part of "mRNA". Announced that it is developing in a new way.
In addition, the group of "VLP Therapeutics Japan" introduced a vaccine with a new mechanism that can be expected to have the same effect as before by using a very small amount of RNA, and a concrete clinical trial will be conducted within this month. Announced that it will submit its plan to a national agency.